| Oct 25 |
Sanofi posts Q3 revenue beat as Dupixent sales jump
|
| Oct 25 |
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
|
| Oct 25 |
Sanofi Earnings Get Boost From Early Vaccine Sales
|
| Oct 25 |
Trending tickers: Tesla, Lloyds, Capri, Deckers and Mercedes-Benz
|
| Oct 25 |
Sanofi: Q3 Earnings Snapshot
|
| Oct 25 |
Sanofi Profit Lifted by Early Vaccine Sales, Dupixent Growth
|
| Oct 25 |
Sanofi Non-GAAP EPS of €2.25, revenue of €3.44B, gives FY guidance
|
| Oct 25 |
Sanofi profit growth beats market view on early start of vaccine sales
|
| Oct 25 |
Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
|
| Oct 24 |
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
|
